June 2019 - Volume 3 - Issue - Contributor Index

Author:
Ta, F.

GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS: PS1518

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3:699-700, June 2019.

Author:
Ta, T.

GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS: PS1518

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3:699-700, June 2019.

Author:
Tabayashi, T.
Author:
Tabbaa, D.

GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS: PS1518

Heath, J.; de Dreuzy, E.; Sanchez, M.; More

HemaSphere. 3:699-700, June 2019.

MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA: PF670

Díaz, Á.; Larrán, Álvarez A.; Casterá, Mora E.; More

HemaSphere. 3:288, June 2019.

Author:
Taborda, G.
Author:
Tacchetti, P.

A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS: PF560

Martello, M.; Termini, R.; Borsi, E.; More

HemaSphere. 3:232, June 2019.

Author:
Tachawong, N.
Author:
Tachdjian, G.
Author:
Tachi, N.

SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION: PS1435

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3:661-662, June 2019.

Author:
Tachita, T.

COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN: PS1367

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3:624-625, June 2019.

RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOME: PF191

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3:47-48, June 2019.

Author:
Tada, K.
Author:
Tadele, D.

MASS CYTOMETRY REVEAL EARLY SIGNALING RESPONSES TO INDUCTION THERAPY IN IMMUNOPHENOTYPICALLY DEFINED LEUKEMIC CELL SUBSETS THAT PREDICT SURVIVAL IN AML: S835

Tislevoll, B. S.; Fagerholt, O. H.E.; Hellesøy, M.; More

HemaSphere. 3:371-372, June 2019.

Author:
Tadmor, B.
Author:
Tadmor, T.
Author:
Tafulo, S.
Author:
Tafuri, A.
Author:
Tafuri, M.
Author:
Taghon, T.
Author:
Tagliaferri, E.

MULTI-CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS: PF758

Castagna, L.; Dodero, A.; Patriarca, F.; More

HemaSphere. 3:333, June 2019.

Author:
Tagliaferri, L.
Author:
Tagliaferri, P.

SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES: S121

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3:12-13, June 2019.

Author:
Tagliafico, E.

PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS: PF655

Rontauroli, S.; Zini, R.; Bianchi, E.; More

HemaSphere. 3:280-281, June 2019.

Author:
Tagliavini, A.
Author:
Taguchi, M.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

Author:
Taha, G.
Author:
taha, H.
Author:
Taha, R. Y

COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA: PF583

Carrasco-Leon, A.; Ezponda, T.; Meydan, C.; More

HemaSphere. 3:243, June 2019.

Author:
Taha, R. Y.

CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA: PF567

Ordoñez, R.; Kulis, M.; Russiñol, N.; More

HemaSphere. 3:236, June 2019.

Author:
Taher, A.
Author:
Taher, A. T.
Author:
Tai, Y.-T.
Author:
Taiana, E.
Author:
Taja-Chayeb, L.
Author:
Tajana, M.

PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE: PF227

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3:65-66, June 2019.

Author:
Tajima, A.
Author:
Takahashi, H.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

Author:
Takahashi, K.

A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES: PF291

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3:97, June 2019.

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML): PF673

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3:289-290, June 2019.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS): PS1064

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3:481-482, June 2019.

FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP): PS1180

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3:537, June 2019.

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.: S1615

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3:745, June 2019.

Author:
Takahashi, N.

ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): PF411

Mahon, F.-X.; Boquimpani, C.; Takahashi, N.; More

HemaSphere. 3:158, June 2019.

Author:
Takahashi, S.
Author:
Takahashi, Y.
Author:
Takamatsu, H.
Author:
Takami, A.
Author:
Takami, H.
Author:
Takami, K.
Author:
Takamori, H.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

Author:
Takano, K.

SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION: PS1435

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3:661-662, June 2019.

Author:
Takao, T.
Author:
Takaori, A.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

Author:
Takashima, S.
Author:
Takasugi, S.
Author:
Takayama, N.

COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PF784

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3:345-346, June 2019.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

Author:
Takeda, J.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

Author:
Takei, M.
Author:
Takeshita, J.

EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: PS1277

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3:584-585, June 2019.

SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY: S1639

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3:758, June 2019.

Author:
Takeuchi, M.
Author:
Takeuchi, Y.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

Author:
Takezako, N.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY: PS1370

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3:626-627, June 2019.

Author:
Takimoto, C.

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS: S867

Advani, R.; Bartlett, N.; Smith, S.; More

HemaSphere. 3:388, June 2019.

MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION: PS1354

Kuwahara-Ota, S.; Shimura, Y.; Isa, R.; More

HemaSphere. 3:619, June 2019.

Author:
Takizawa, J.

CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012): PS1263

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3:578, June 2019.

Author:
Taktybayeva, A.

IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-ARM, MULTICENTER, PHASE 2 TRIAL: PF374

Davids, M. S.; Brander, D. M.; Kim, H. T.; More

HemaSphere. 3:138-139, June 2019.

Author:
Talami, A.

LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE: PB2324

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3:1036, June 2019.

Author:
Talamo, G.

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT: PF631

Reece, D.; Bahlis, N. J.; Samaras, C.; More

HemaSphere. 3:268-269, June 2019.

Author:
Talbi, T. F.
Show: